BCG unresponsive patientsI watched the recent video embedded in the stockhouse article. I know it has been discussed before, but I am still confused as to why TLT market is "only" the BCG unresponsive patients? Assuming positive results of Phase II, why not attacking the primary standard of care altogether and replace BCG? What are the procedures to replace BCG and obviously increase TLT market share in the NMIBC market? Thanks! Moulouk